ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species

Wong, Puiian; Lv, Zheng; Li, Jinglan; Wei, Qiushi; Xu, LiangLiang*; Fang, Bin*; Luo, Yiwen*; He, Mincong*广州中医药大学; 1
Oxidative Medicine and Cellular Longevity2022-11-4DOI: 10.1155/2022/5982014
6被引18阅读
引用收藏
分享

摘要

Dysregulation of osteoclast-osteoblast balance, resulting in abnormal bone remodeling, is responsible for postmenopausal osteoporosis (PMOP) or other secondary forms of osteoporosis. We demonstrated that dictamnine (DIC), a novel RANKL-targeted furoquinoline alkaloid, inhibits osteoclastogenesis by facilitating the activities of reactive oxygen species (ROS), NF-kappa B, and NFATc1 in vitro and prevents the development of OVX-induced osteoporosis mouse models in vivo. Methods. The docking mechanism of DIC and RANKL was initially identified by protein-ligand molecular docking. RNA sequencing was performed and analyzed to reveal the potential mechanism and signaling pathway of the antiosteoporosis effects of DIC. To verify the sequencing results, we examined the impact of DIC on RANKL-induced osteoclast differentiation, bone resorption, F-actin ring production, ROS generation, and NF-kappa B activation in osteoclasts in vitro. Moreover, a luciferase assay was performed to determine the binding and transcriptional activity of Nrf2 and NF-kappa B. The in vivo efficacy of DIC was assessed with an ovariectomy- (OVX-) induced osteoporosis model, which was analyzed using micro-CT and bone histomorphometry. Results. The molecular docking results indicated that DIC could bind particularly to RANKL. RNA-seq confirmed that DIC could regulate the osteoclast-related pathway. DIC suppressed osteoclastogenesis, bone resorption, F-actin belt formation, osteoclast-specific gene expression, and ROS activity by preventing NFATc1 expression and affecting NF-kappa B signaling pathways in vitro. The luciferase assay showed that DIC not only suppressed the activity of Nrf2 but also contributed to the combination of Nrf2 and NF-kappa B. Our in vivo study indicated that DIC protects against OVX-induced osteoporosis and preserves bone volume by inhibiting osteoclast activity and function. Conclusions. DIC can ameliorate osteoclast formation and OVX-induced osteoporosis and therefore is a potential therapeutic treatment for osteoporosis.

学科与关键词

关键词
POSTMENOPAUSAL WOMENOSTEOCLASTOGENESISNFATC1DIFFERENTIATIONIDENTIFICATIONINFLAMMATIONPREVENTIONBINDING
相关
加载中…
  • A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species
    Hong, Guoju; Chen, Zhenqiu; Han, Xiaorui; Zhou, Lin; Pang, Fengxiang; Wu, Rishana; Shen, Yingshan; He, Xiaoming; Hong, Zhinan; Li, Ziqi; He, Wei; Wei, Qiushi*Clinical and Translational Medicine, 2021, 11(5): e392.被引 31
  • Bindarit Reduces Bone Loss in Ovariectomized Mice by Inhibiting CCL2 and CCL7 Expression via the NF-κB Signaling Pathway
    Yuan, Shi-Guo; Hu, Hong-Ling; Wang, Xin-Jia; Yang, Jin-Cheng; Zhou, Rong-Ping; Bai, Xiao-Chun*; Lai, Ping-Lin*Orthopaedic Surgery, 2022, 14(6): 1203-1216.被引 4
  • Anemoside B4 attenuates RANKL-induced osteoclastogenesis by upregulating Nrf2 and dampens ovariectomy-induced bone loss
    Cao, Zhen; Niu, Xuben; Wang, Maihuan; Yu, Siwang; Wang, Mingkun; Mu, Silong; Liu, Chuan*; Wang, Yaxi*Biomedicine and Pharmacotherapy, 2023, 167: 115454.
查看全部 →

发表信息

论文状态
公开发表
期刊
Oxidative Medicine and Cellular Longevity
发表日期
2022-11-04
卷期
第 2022 卷
页码
5982014
DOI
10.1155/2022/5982014
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National National Natural Science Foundation of China; Science Foundation of Guangzhou; [81473696]; [82274544]; [82004392]; [202102020890]

作者

  • W

    Wong, Puiian (第一作者)

    guangzhou univ chinese med

  • L

    Lv, Zheng

    1 · guangzhou univ chinese med

查看全部 8 位作者收起作者
  • L

    Li, Jinglan

    1 · guangzhou univ chinese med

  • W

    Wei, Qiushi

    guangzhou univ chinese med

  • X

    Xu, LiangLiang (通讯)

    guangzhou univ chinese med

  • F

    Fang, Bin (通讯)

    1 · guangzhou univ chinese med

  • L

    Luo, Yiwen (通讯)

    guangzhou univ chinese med

  • H

    He, Mincong (通讯)

    guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417